Table 3.

Cox regression analysis for factors possibly influencing OS and DFS in patients with cervical cancer

Factors	Recurrence-free survival				Overall survival
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age (≥50 vs <50)	0.138 (0.029–0.648)	0.012	0.104 (0.02–0.567)	0.01	0.111 (0.023–0.527)	0.005	0.6 (0.397–0.906)	0.015
Tumor size (≥4 vs <4 cm)	1.117 (1.03–1.452)	0.002	0.156 (0.029–1.217)	0.079	1.95 (1.024-1.375)	0.001	0.336 (0.186–1.609)	0.082
Histology (well and moderate vs poor)	0.346 (0.1–1.196)	0.094	0.365 (0.086–1.543)	0.173	1.042 (0.682–1.590)	0.196	0.447 (0.128–1.563)	0.207
LN metastasis (absent vs present)	5.378 (1.556–18.58)	0.008	0.467 (0.078–2.774)	0.404	5.111 (1.479–17.659)	0.01	0.592 (0.311–1.126)	0.455
Vascular space involvement (absent vs present)	12.262 (1.553–96.82)	0.017	1.612 (0.057–38.489)	0.805	11.737 (1.487–92.552)	0.019	0.777 (0.401–1.505)	0.565
Lymphatic invasion (absent vs present)	10.125 (1.213–85.32)	0.021	7.531 (0.325–156.960)	0.239	11.894 (1.507–93.909)	0.017	1.202 (0.642–2.252)	0.746
Deep stromal invasion (absent vs present)	8.498 (1.076–67.086)	0.042	2.498 (0.323–26.631)	0.45	8.97 (1.135–70.892)	0.038	5.733 (0.593–55.392)	0.702
Podoplanin (positive vs negative)	10.759 (1.363–84.944)	0.024	0.853 (0.023–31.877)	0.932	11.363 (1.438–69.791)	0.021	3.238 (0.349–30.078)	0.878
Vimentin (positive vs negative)	11.959 (2.535–56.407)	0.002	11.213 (1.67–41.774)	0.003	12.515 (2.649–59.121)	0.001	8.386 (1.475–47.66)	0.012
TP53 (positive vs negative)	6.443 (1.815–22.873)	0.004	3.467 (0.929–12.946)	0.654	7.768 (2.161–27.918)	0.006	2.284 (0.521–10.014)	0.27

Hazard ratios with 95% confidence intervals (95% CI) were estimated and adjusted by indicated clinical parameters